Literature DB >> 24077952

Anti-apolipoprotein A-1 antibodies and carotid intima-media thickness in Egyptian women with systemic lupus erythematosus.

M M Radwan1, D El-Lebedy, R Fouda, E Elsorougy.   

Abstract

The objective of the study was to evaluate anti-apolipoprotein A-I (Apo A-I) and carotid intima-media thickness (cIMT) as cardiovascular risk factors in Egyptian women with systemic lupus erythematosus (SLE). The study included 160 subjects, 80 women with SLE and 80 healthy women as a control group. Disease activity score (SLEDAI), disease damage index (SLICC/ACR), lipid profile, complement C3 and C4, high-sensitivity CRP (hsCRP), anti-dsDNA and anticardiolipin antibodies were evaluated in addition to anti-Apo A-I antibodies and cIMT. The mean age of patients was 28.35 ± 7.06 years with mean disease duration of 4.58 ± 3.36 years. Anti-Apo A-I antibody titer was significantly higher in SLE patients than in controls (mean 35.3 ± 6.8 vs. 21.4 ± 5.91 U/L; P = 0.000). Carotid ultrasound showed significantly thickened intima in SLE patients compared with control subjects (mean thickness, 0.5 ± 0.08 vs. 0.45 ± 0.06 mm; P = 0.003). Correlation studies with other cardiovascular risk factors demonstrated significant associations between anti-Apo A-I and SLEDAI, SLICC/ACR, C3 and C4. On the other hand, cIMT showed significant association with age, systolic blood pressure, hsCRP and body mass index. Thus, SLE disease activity is associated with a significant increase in anti-Apo A-I titer. Also, increased cIMT might be a cardiovascular risk factor in Egyptian patients with SLE.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24077952     DOI: 10.1007/s10067-013-2399-8

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  35 in total

1.  Anti-apolipoprotein A-1 IgG predicts major cardiovascular events in patients with rheumatoid arthritis.

Authors:  Nicolas Vuilleumier; Sylvette Bas; Sabrina Pagano; Fabrizio Montecucco; Pierre-André Guerne; Axel Finckh; Christian Lovis; François Mach; Denis Hochstrasser; Pascale Roux-Lombard; Cem Gabay
Journal:  Arthritis Rheum       Date:  2010-09

Review 2.  Systemic lupus erythematosus.

Authors:  Anisur Rahman; David A Isenberg
Journal:  N Engl J Med       Date:  2008-02-28       Impact factor: 91.245

Review 3.  The role of preventive cardiology in systemic lupus erythematosus.

Authors:  Jennifer Rae Elliott; Susan Manzi; Daniel Edmundowicz
Journal:  Curr Rheumatol Rep       Date:  2007-05       Impact factor: 4.592

4.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.

Authors:  M C Hochberg
Journal:  Arthritis Rheum       Date:  1997-09

5.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

Authors:  W T Friedewald; R I Levy; D S Fredrickson
Journal:  Clin Chem       Date:  1972-06       Impact factor: 8.327

6.  Comparison of risk factors for vascular disease in the carotid artery and aorta in women with systemic lupus erythematosus.

Authors:  Faith Selzer; Kim Sutton-Tyrrell; Shirley G Fitzgerald; Joan E Pratt; Russell P Tracy; Lewis H Kuller; Susan Manzi
Journal:  Arthritis Rheum       Date:  2004-01

7.  Antibodies toward high-density lipoprotein components inhibit paraoxonase activity in patients with systemic lupus erythematosus.

Authors:  J R Batuca; P R J Ames; D A Isenberg; J Delgado Alves
Journal:  Ann N Y Acad Sci       Date:  2007-06       Impact factor: 5.691

8.  Anti-atherogenic and anti-inflammatory properties of high-density lipoprotein are affected by specific antibodies in systemic lupus erythematosus.

Authors:  J R Batuca; P R J Ames; M Amaral; C Favas; D A Isenberg; J Delgado Alves
Journal:  Rheumatology (Oxford)       Date:  2008-11-10       Impact factor: 7.580

9.  Serum from patients with SLE instructs monocytes to promote IgG and IgA plasmablast differentiation.

Authors:  Hyemee Joo; Christine Coquery; Yaming Xue; Ingrid Gayet; Stacey R Dillon; Marilynn Punaro; Gerard Zurawski; Jacques Banchereau; Virginia Pascual; Sangkon Oh
Journal:  J Exp Med       Date:  2012-06-11       Impact factor: 14.307

10.  Oxidative stress in cardiovascular inflammation: its involvement in autoimmune responses.

Authors:  Elisabetta Profumo; Brigitta Buttari; Rachele Riganò
Journal:  Int J Inflam       Date:  2011-06-28
View more
  5 in total

1.  Lipid profile among girls with systemic lupus erythematosus.

Authors:  Daniele Machado; Roseli O S Sarni; Thaís T O Abad; Simone G L Silva; Eugênia J B Khazaal; Sonia Hix; Milena S G Correia; Fabíola I Suano-Souza; Claudio A Len; Maria Teresa R A Terreri
Journal:  Rheumatol Int       Date:  2015-11-16       Impact factor: 2.631

Review 2.  ApoA1 and ApoA1-specific self-antibodies in cardiovascular disease.

Authors:  Dimitry A Chistiakov; Alexander N Orekhov; Yuri V Bobryshev
Journal:  Lab Invest       Date:  2016-05-16       Impact factor: 5.662

3.  IgG anti-apolipoprotein A-1 antibodies in patients with systemic lupus erythematosus are associated with disease activity and corticosteroid therapy: an observational study.

Authors:  Sara Croca; Paul Bassett; Sharon Chambers; Maria Davari; Karim Fouad Alber; Oliver Leach; Yiannis Ioannou; Ian Giles; David Isenberg; Anisur Rahman
Journal:  Arthritis Res Ther       Date:  2015-02-09       Impact factor: 5.156

4.  Anti-Apolipoprotein A-1 IgG Predict All-Cause Mortality and Are Associated with Fc Receptor-Like 3 Polymorphisms.

Authors:  Panagiotis Antiochos; Pedro Marques-Vidal; Julien Virzi; Sabrina Pagano; Nathalie Satta; Oliver Hartley; Fabrizio Montecucco; François Mach; Zoltán Kutalik; Gerard Waeber; Peter Vollenweider; Nicolas Vuilleumier
Journal:  Front Immunol       Date:  2017-04-18       Impact factor: 7.561

5.  Definition of human apolipoprotein A-I epitopes recognized by autoantibodies present in patients with cardiovascular diseases.

Authors:  Priscila Camillo Teixeira; Axel Ducret; Philippe Ferber; Hubert Gaertner; Oliver Hartley; Sabrina Pagano; Michelle Butterfield; Hanno Langen; Nicolas Vuilleumier; Paul Cutler
Journal:  J Biol Chem       Date:  2014-08-28       Impact factor: 5.157

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.